NO20002691L - IFNAR2/IFN kompleks - Google Patents

IFNAR2/IFN kompleks

Info

Publication number
NO20002691L
NO20002691L NO20002691A NO20002691A NO20002691L NO 20002691 L NO20002691 L NO 20002691L NO 20002691 A NO20002691 A NO 20002691A NO 20002691 A NO20002691 A NO 20002691A NO 20002691 L NO20002691 L NO 20002691L
Authority
NO
Norway
Prior art keywords
ifn
complex
ifnar
interferon
peptide
Prior art date
Application number
NO20002691A
Other languages
English (en)
Other versions
NO20002691D0 (no
Inventor
Mark Tepper
Mark Cunningham
David Sherris
Nabil El Tayar
Sean Mckenna
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20002691D0 publication Critical patent/NO20002691D0/no
Publication of NO20002691L publication Critical patent/NO20002691L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Det er beskrevet at in vivo effekten av Type I interferon (IFN) kan bli forlenget ved å administrere interferonet i form av et kompleks med en EFN bindende kjede til den human interferon ct/p reseptoren (IFNAR). Et slikt kompleks forbedrer også stabiliteten til IFN og øker styrken til IFN. Komplekset kan være et ikke-kovalent kompleks eller et der IFN og IFNAR er bundet med en kovalent binding eller et peptid. Når IFN er bundet ved en peptidbinding i form av et fusjonsprotein kan IFN bli separert fra IFNAR ved hjelp av en peptidkobler. Et slikt fusjonsprotein kan bli produsert ved rekombinant DNA teknologi. Å lagre IFN i form av et slikt kompleks forbedrer lagringslivet til IFN, og tillater lagring under mildere forhold enn det som ellers ville være mulig.
NO20002691A 1997-12-19 2000-05-25 IFNAR2/IFN kompleks NO20002691L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6829597P 1997-12-19 1997-12-19
PCT/US1998/026926 WO1999032141A1 (en) 1997-12-19 1998-12-18 Ifnar2/ifn complex

Publications (2)

Publication Number Publication Date
NO20002691D0 NO20002691D0 (no) 2000-05-25
NO20002691L true NO20002691L (no) 2000-08-18

Family

ID=22081665

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002691A NO20002691L (no) 1997-12-19 2000-05-25 IFNAR2/IFN kompleks

Country Status (28)

Country Link
US (1) US6372207B1 (no)
EP (1) EP1037658B1 (no)
JP (1) JP4601163B2 (no)
KR (1) KR100593981B1 (no)
CN (1) CN1241638C (no)
AR (1) AR020315A1 (no)
AT (1) ATE218362T1 (no)
AU (1) AU755078B2 (no)
BG (1) BG64920B1 (no)
BR (1) BR9813753A (no)
CA (1) CA2311648C (no)
DE (1) DE69805844T2 (no)
DK (1) DK1037658T3 (no)
EA (1) EA003635B1 (no)
EE (1) EE200000355A (no)
ES (1) ES2174530T3 (no)
HK (1) HK1032914A1 (no)
HU (1) HUP0100456A3 (no)
IL (2) IL136855A0 (no)
NO (1) NO20002691L (no)
NZ (1) NZ504771A (no)
PL (1) PL197568B1 (no)
PT (1) PT1037658E (no)
SK (1) SK9222000A3 (no)
TR (1) TR200001961T2 (no)
UA (1) UA74132C2 (no)
WO (1) WO1999032141A1 (no)
ZA (1) ZA9811634B (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation
US7138379B2 (en) * 2000-07-26 2006-11-21 Schering Aktiengesellschaft Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons
IL147414A0 (en) 2001-12-31 2002-08-14 Yeda Res & Dev Ifnar2 mutants, their production and use
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
AU2004266969B2 (en) * 2003-08-25 2010-02-25 Taniguchi, Tadatsugu Interferon-beta composite
CN100400664C (zh) * 2005-09-06 2008-07-09 中国人民解放军第四军医大学 肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
GB0815216D0 (en) * 2008-08-21 2008-09-24 Asterion Ltd Interleukin
EP2413958A4 (en) 2009-03-31 2014-04-02 Univ East Carolina CYTOKINES AND NEUROANTIGENES FOR THE TREATMENT OF IMMUNE DISEASES
KR101293363B1 (ko) * 2011-02-28 2013-08-05 성균관대학교산학협력단 인터페론 수용체 유전자를 포함하는 조류독감 예방용 조성물
EP2970461A4 (en) * 2013-03-15 2016-11-23 Janssen Biotech Inc INTERFERON ALPHA AND OMEGA ANTIBODY ANTAGONISTS
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
US20200123227A1 (en) * 2017-06-20 2020-04-23 The Board Of Regents Of The University Of Texas System Interferon prodrug for the treatment of cancer
EP3672986A1 (en) 2017-08-22 2020-07-01 Sanabio, LLC Soluble interferon receptors and uses thereof
CN112646783B (zh) * 2020-12-30 2023-12-01 广州医科大学附属市八医院 表达基因、经基因修饰的受精卵的构建方法和小鼠模型的构建方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821078A (en) * 1992-09-03 1998-10-13 Yeda Research And Development Co. Ltd. Nucleic acid encoding interferon-α/β binding protein
IL106591A (en) 1992-09-03 2008-03-20 Yeda Res & Dev Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it
IL107378A (en) * 1993-10-24 2005-05-17 Yeda Res & Dev SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE

Also Published As

Publication number Publication date
HUP0100456A3 (en) 2003-09-29
EP1037658B1 (en) 2002-06-05
CA2311648C (en) 2010-11-16
CN1241638C (zh) 2006-02-15
JP2001526242A (ja) 2001-12-18
PT1037658E (pt) 2002-10-31
AR020315A1 (es) 2002-05-08
KR100593981B1 (ko) 2006-06-30
DE69805844T2 (de) 2002-10-24
SK9222000A3 (en) 2001-01-18
NZ504771A (en) 2002-09-27
PL341423A1 (en) 2001-04-09
HUP0100456A1 (hu) 2001-06-28
BG104539A (en) 2001-04-30
KR20010032836A (ko) 2001-04-25
US6372207B1 (en) 2002-04-16
AU1926999A (en) 1999-07-12
NO20002691D0 (no) 2000-05-25
HK1032914A1 (en) 2001-08-10
WO1999032141A1 (en) 1999-07-01
JP4601163B2 (ja) 2010-12-22
IL136855A (en) 2007-07-24
CN1282255A (zh) 2001-01-31
UA74132C2 (uk) 2005-11-15
ATE218362T1 (de) 2002-06-15
CA2311648A1 (en) 1999-07-01
EA200000685A1 (ru) 2000-12-25
TR200001961T2 (tr) 2000-11-21
AU755078B2 (en) 2002-12-05
BG64920B1 (bg) 2006-09-29
DE69805844D1 (de) 2002-07-11
PL197568B1 (pl) 2008-04-30
DK1037658T3 (da) 2002-09-30
EP1037658A1 (en) 2000-09-27
IL136855A0 (en) 2001-06-14
BR9813753A (pt) 2000-10-10
EA003635B1 (ru) 2003-08-28
ZA9811634B (en) 1999-06-22
EE200000355A (et) 2001-10-15
ES2174530T3 (es) 2002-11-01

Similar Documents

Publication Publication Date Title
NO20002691L (no) IFNAR2/IFN kompleks
Lortat-Jacob et al. Interferon-γ binds to heparan sulfate by a cluster of amino acids located in the C-terminal part of the molecule
ES2307718T3 (es) Peptido 2 similar al flucagon (glp-2) de duracion prolongada para el tratamiento de enfermedades y trastornos gastrointestinales.
WO2003094849A3 (en) Ferritin fusion proteins for use in vaccines and other applications
DK1105409T3 (da) Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter
JP2006514607A5 (no)
DE69331832T2 (de) Diagnostische verfahren und pharmazeutische zusammensetzungen auf der basis von notch-proteinen und nukleinsäuren
DK0661989T3 (da) Proteinsammensætninger med vedvarende frigivelse
ATE348883T1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
ATE350049T1 (de) Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1
JP2001526242A5 (no)
DE69328035D1 (de) Polypeptide, von endonexin 2 stammend, mit hepatitis b virus rezeptor aktivität und deren verwendungen in diagnotischen und pharmazeutischen zusammensetzungen
ATE258061T1 (de) Tri-, tetra-, penta- und polypeptide und ihre therapeutische verwendung als antidepressiva
JPH01131197A (ja) Ａｎｆ活性を有するペプチド類
DE69712182D1 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
WO2002036628A3 (en) New multimeric interferon beta polypeptides
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
Class et al. Patent application title: REVERSIBLE PEGYLATED DRUGS Inventors: Yoram Shechter (Rehovot, IL) Yoram Shechter (Rehovot, IL) Matityahu Fridkin (Rehovot, IL) Matityahu Fridkin (Rehovot, IL) Haim Tsubery (Elad, IL)
NZ513915A (en) Chimeric proteins comprising 6 contiguous amino acids that bind to the GIT fused to a second protein, which may be a drug
AU2003274173A1 (en) Peptides and recombinant proteins mimicking interferons
Wallin Studies on vasoactive peptides derived from human fibrin and fibrinogen degraded by plasmin or leucocyte elastase.
ES2051152B1 (es) Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados.
JP2001278895A (ja) インターフェロン作用増強性ペプチド及び該ペプチドとインターフェロンとを含有するインターフェロン作用増強組成物

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application